1.42
+0.02(+1.43%)
Currency In USD
| Previous Close | 1.4 |
| Open | 1.38 |
| Day High | 1.51 |
| Day Low | 1.34 |
| 52-Week High | 6.78 |
| 52-Week Low | 0.87 |
| Volume | 436,644 |
| Average Volume | 910,754 |
| Market Cap | 141.99M |
| PE | -1.13 |
| EPS | -1.26 |
| Moving Average 50 Days | 1.32 |
| Moving Average 200 Days | 2.44 |
| Change | 0.02 |
If you invested $1000 in Alector, Inc. (ALEC) since IPO date, it would be worth $78.54 as of July 02, 2025 at a share price of $1.42. Whereas If you bought $1000 worth of Alector, Inc. (ALEC) shares 5 years ago, it would be worth $59.64 as of July 02, 2025 at a share price of $1.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 03, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire Inc.
May 08, 2025 8:05 PM GMT
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer’s disease Continuing to pursue Alector Brain Carrier prog
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
GlobeNewswire Inc.
Apr 17, 2025 12:00 PM GMT
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Na